Literature DB >> 27630522

Aripiprazole Lauroxil (Aristada): An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia.

Martin P Cruz.   

Abstract

Aripiprazole lauroxil (Aristada) for the treatment of schizophrenia.

Entities:  

Year:  2016        PMID： 27630522      PMCID： PMC5010264     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  1 in total

1.  The Economic Burden of Schizophrenia in the United States in 2013.

Authors:  Martin Cloutier; Myrlene Sanon Aigbogun; Annie Guerin; Roy Nitulescu; Agnihotram V Ramanakumar; Siddhesh A Kamat; Michael DeLucia; Ruth Duffy; Susan N Legacy; Crystal Henderson; Clement Francois; Eric Wu
Journal:  J Clin Psychiatry       Date:  2016-06       Impact factor: 4.384
  1 in total
  9 in total

Review 1.  New Antipsychotic Medications in the Last Decade.

Authors:  Mehak Pahwa; Ahmad Sleem; Omar H Elsayed; Megan Elizabeth Good; Rif S El-Mallakh
Journal:  Curr Psychiatry Rep       Date:  2021-11-29       Impact factor: 5.285

2.  Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.

Authors:  Marjie L Hard; Richard J Mills; Brian M Sadler; Angela Y Wehr; Peter J Weiden; Lisa von Moltke
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

3.  Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.

Authors:  Marjie L Hard; Richard J Mills; Brian M Sadler; Ryan Z Turncliff; Leslie Citrome
Journal:  J Clin Psychopharmacol       Date:  2017-06       Impact factor: 3.153

4.  Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.

Authors:  Marjie L Hard; Angela Y Wehr; Brian M Sadler; Richard J Mills; Lisa von Moltke
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-08       Impact factor: 2.441

5.  Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia.

Authors:  Joseph P McEvoy; Peter J Weiden; Paul H Lysaker; Xiaowu Sun; Amy K O'Sullivan
Journal:  BMC Psychiatry       Date:  2021-03-24       Impact factor: 3.630

Review 6.  Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.

Authors:  Kunal Maini; Haley Gould; Jessica Hicks; Fatima Iqbal; James Patterson; Amber N Edinoff; Elyse M Cornett; Adam M Kaye; Omar Viswanath; Ivan Urits; Alan D Kaye
Journal:  Neurol Int       Date:  2021-07-01

Review 7.  Novel treatment options in depression and psychosis.

Authors:  Eva Ceskova; Petr Silhan
Journal:  Neuropsychiatr Dis Treat       Date:  2018-03-13       Impact factor: 2.570

8.  Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.

Authors:  Marjie L Hard; Angela Y Wehr; Yangchun Du; Peter J Weiden; David Walling; Lisa von Moltke
Journal:  J Clin Psychopharmacol       Date:  2018-10       Impact factor: 3.153

Review 9.  Lipids and Lipid-Processing Pathways in Drug Delivery and Therapeutics.

Authors:  Milica Markovic; Shimon Ben-Shabat; Aaron Aponick; Ellen M Zimmermann; Arik Dahan
Journal:  Int J Mol Sci       Date:  2020-05-04       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.